Cancer is a disease of aging. Most patients are over 60. That's why the adult and geriatric demographics dominate the mRNA cancer vaccine market. The mRNA cancer vaccines and therapeutics market forecast shows that adults (40‑65) hold the largest share, but geriatric (65+) is the fastest‑growing. Why? Because the immune system weakens with age — but mRNA vaccines can still work.

What's different for older patients? They often have multiple comorbidities and take many medications. The mRNA cancer vaccines market analysis notes that subcutaneous administration is growing faster than intramuscular for older patients — smaller needle, less pain. And geriatric patients prefer at‑home or community centre dosing rather than hospital visits.

But clinical trials often exclude older patients due to frailty. That's a problem, because cancer incidence peaks in the elderly. Advocacy groups are pushing for more inclusive trials.

The takeaway: if you're over 65 and have cancer, don't assume you're too old for a vaccine trial. Age alone shouldn't disqualify you. Talk to your oncologist about options.